Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Children with better, longer sleep more likely to have better weight

09 Nov 2019
The growing obsession with the internet is one of the reasons leading to sleep deprivation.

Longer sleep in children is tied to reduced body mass index (BMI) and lower risks of becoming overweight or obese, regardless of socioeconomic status, a recent study has found.

Researchers performed a cross-sectional analysis on 382 children (mean age, 8.47±0.45 years; 49.5 percent female), a quarter of whom were living at or below the poverty line. Participants were assessed at 12 months of age for their socioeconomic status, while sleep and weight indicators were evaluated at 8 years of age.

Longer sleep duration at 8 years correlated with significantly lower BMI (estimate, –0.50±0.23; p≤0.05) and the risk of becoming overweight or obese (odds ratio, 0.52, 95 percent confidence intervals [CI], 0.34–0.78; p≤0.01). No such effect was reported for percent body fat and waist circumference.

Moreover, socioeconomic status both at 12 months and at 8 years of life was not associated with any of the weight indicators.

Notably, despite having no main relationship with BMI, the effect of sleep efficiency appeared to be modified by early life socioeconomic status. In particular, greater sleep efficiency was significantly predictive of lower BMI only in children belonging to families of low socioeconomic status (p<0.001). In absolute terms, each 5-percent increase in sleep efficiency led to a 0.5-point decrease in BMI.

“Findings identify early socioeconomic status as a potent moderator of associations between sleep and weight indicators in middle childhood and inform clinicians that maximizing and improving child sleep quantity and quality may be candidate targets for interventions looking to reduce BMI and obesity, particularly for children who experience fewer resources early in life,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.